Navigation Links
Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
Date:10/27/2008

Brad Nutter to Continue in Role of Chairman of the Board

BRAINTREE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today that Brian Concannon will be promoted to the position of President and CEO effective in April 2009, succeeding Brad Nutter in this role. Brian will also join the Haemonetics Board of Directors at that time. Brad Nutter will continue as Chairman and CEO until April 2009 and thereafter will remain an employee of the Company as Executive Chairman of the Haemonetics Board of Directors.

Brian Concannon joined Haemonetics in September 2003 as President of the Patient Division following an eighteen year career with progressively responsible leadership roles with American Hospital Supply Corporation, Baxter Healthcare Corporation, Allegiance Healthcare, and Cardinal Health Products and Services. As President of our Patient Division, Mr. Concannon led the expansion of our selling organization in concert with our decision to take direct the OrthoPAT(R) orthopedic perioperative autotransfusion product line. In 2006, he was promoted to President of Global Markets where he led the transformation of our businesses in Asia, Japan and Europe. In 2007, Mr. Concannon's responsibilities were again expanded to encompass oversight of all of our geographic sales and marketing operations and established lines of business as our Chief Operating Officer. Mr. Concannon is a 1979 graduate of the U.S. Military Academy at West Point, with a B.S. degree in engineering.

Ron Gelbman, Lead Director of the Board of Directors said, "Brad has made significant contributions to the growth of the company and the creation of shareholder value over the past six years. The Board appreciates his continued leadership in the role of Executive Chairman where he will focus on corporate governance and supporting the implementation of Haemonetics' corporate vision. We are also delighted by the appointment of Brian Concannon as President and CEO, effective in April 2009. This transition has been anticipated as part of the Company's Succession Plan and we are confident in Brian's leadership."

"Brian has the ideal experience to continue to lead Haemonetics to realize our vision as The Blood Management Company. This appointment is part of a leadership succession process which we have methodically developed over the past several years, and I am excited about continuing to work with Brian and the Haemonetics leadership team," said Brad Nutter, Chairman and CEO.

Mr. Concannon added, "I'm delighted to have this opportunity to lead the next phases of the growth of Haemonetics. Our trajectory over the past several years gives us tremendous momentum to build upon. We have a winning vision and strategy, a strong product portfolio, a balanced global footprint, and a great leadership team - all of which position us for continued leadership in our industry. I look forward to this opportunity to build upon our achievements and continue to create and sustain shareholder value."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

Contact:

Julie Fallon

Tel. (781) 356-9517

Alt. Tel. (617) 320-2401


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
9. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
10. Haemonetics Sets Date for First Quarter Fiscal Year 2009 Earnings Release and Conference Call - August 1, 2008
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... System and David Konur, CEO of Cardiovascular Institute of the South announced today ... be performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, ... Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and ... Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession of Aging ... our aging population has on communities and resources. Aging Life Care plays an important ... age-related challenges. , Aging Life Care is a holistic, client-centered approach to caring ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. ... announced a development collaboration with the Australian critical medicine company, Phebra Pty ... schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, including ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous ... to all vaping products that entered the market since February 15, 2007. That ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... 2016 According to market research "Global ... Forecast to 2022 - Industry Insights by Slice Type (High, ... Others)" by P&S Market Research, the global computed tomography ... it is expected to grow at a CAGR of 5.0% ... segment is expected to witness the faster growth, CAGR of ...
Breaking Medicine Technology: